Baidu
map

2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南

2016-05-27 美国临床肿瘤学会 JCO.2016.67.0182

2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南 

中文标题:

2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南

英文标题:

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Can

发布机构:

美国临床肿瘤学会

发布日期:

2016-05-27

简要介绍:

2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南 

相关资料下载:
[AttachmentFileName(sort=100, fileName=2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南)] GetToolGuiderByIdResponse(projectId=1, id=fc2501c0011910d1, title=2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南, enTitle=Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Can, guiderFrom=JCO.2016.67.0182, authorId=null, author=, summary=2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南 , cover=, journalId=null, articlesId=null, associationId=8, associationName=美国临床肿瘤学会, associationIntro=美国临床肿瘤学会(ASCO,American Society of Clinical Oncology)是一个成立于1964年的非营利性组织,总目标是改善肿瘤的监护与预防。目前已有27000名肿瘤科医师加入了ASCO,分属各个肿瘤专科和亚专科。会员包括在肿瘤治疗各个层次的医师和卫生保健专业人员。ASCO由一个有19名成员的当选董事会管理,该学会的大部分业务是由志愿为学会项目花费时间和出力的ASCO会员组成的各种委员会处理的。患者支持团体的领导也经常活跃于ASCO委员会中。目前有22个由ASCO的全职人员管理和支持的委员会。, copyright=0, guiderPublishedTime=Fri May 27 20:27:46 CST 2016, originalUrl=, linkOutUrl=, content=2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南 , tagList=[TagDto(tagId=30603, tagName=HER2阴性), TagDto(tagId=95614, tagName=阳性乳腺癌), TagDto(tagId=100695, tagName=优化化疗方案)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=null, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4227, appHits=139, showAppHits=17, pcHits=3433, showPcHits=1097, likes=296, shares=6, comments=2, approvalStatus=1, publishedTime=Fri May 27 12:27:46 CST 2016, publishedTimeString=2016-05-27, pcVisible=1, appVisible=1, editorId=5295946, editor=kelly, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=kelly, createdTime=Fri May 27 12:27:46 CST 2016, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:27:16 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南)])
2016 ASCO:HER2阴性乳腺癌的优化化疗方案选择和HER2阳性乳腺癌的辅助靶向治疗临床实践指南
下载请点击:
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=95628, encodeId=df2995628d8, content=下载啦!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 06:02:00 CST 2016, time=2016-08-03, status=1, ipAttribution=)]
    2016-08-03 1dd8c52fm63(暂无匿称)

    下载啦!

    0

Baidu
map
Baidu
map
Baidu
map